BGM Group Ltd. (NASDAQ:BGM) Sees Large Growth in Short Interest

Posted by Geri Gentry on Jun 11th, 2026

BGM Group Ltd. (NASDAQ:BGM – Get Free Report) was the recipient of a large increase in short interest in May. As of May 29th, there was short interest totaling 253,222 shares, an increase of 603.1% from the May 14th total of 36,015 shares. Based on an average daily volume of 199,739 shares, the short-interest ratio is presently 1.3 days. Currently, 0.6% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d)” rating on shares of BGM Group in a research note on Monday, April 20th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

View Our Latest Analysis on BGM

BGM Group Price Performance

Shares of BGM stock traded down $0.07 during trading hours on Thursday, reaching $0.36. The company had a trading volume of 663,861 shares, compared to its average volume of 294,090. The stock has a fifty day moving average of $0.31 and a 200-day moving average of $2.21. BGM Group has a 12-month low of $0.26 and a 12-month high of $16.61.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of BGM. Marshall Wace LLP purchased a new position in shares of BGM Group during the second quarter worth $218,000. Mariner LLC acquired a new stake in BGM Group in the third quarter valued at $267,000. Finally, Geode Capital Management LLC acquired a new stake in BGM Group in the second quarter valued at $412,000.

BGM Group Company Profile

(Get Free Report)

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions.